Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the inc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Swain, S. M., Schneeweiss, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortes, J., Baselga, J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834072/
https://ncbi.nlm.nih.gov/pubmed/28057664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw695
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados